hypericin has been researched along with Alzheimer Disease in 2 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with hypericin (5 μM and 15 μM) significantly suppresses oligomeric Aβ42 (oAβ42)-induced expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF α) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity." | 5.43 | Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1. ( Li, P; Qian, F; Wang, Y; Xu, X; Zhang, M, 2016) |
| "Alzheimer's disease (AD) and type 2 diabetes (T2D) are two of the most common diseases in elderly population and they have a high rate of comorbidity." | 1.91 | Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning. ( Gao, LH; Ma, QH; Wang, J; Yan, F; Yuan, X, 2023) |
| "Pretreatment with hypericin (5 μM and 15 μM) significantly suppresses oligomeric Aβ42 (oAβ42)-induced expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF α) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity." | 1.43 | Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1. ( Li, P; Qian, F; Wang, Y; Xu, X; Zhang, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, X | 1 |
| Yan, F | 1 |
| Gao, LH | 1 |
| Ma, QH | 1 |
| Wang, J | 1 |
| Zhang, M | 1 |
| Wang, Y | 1 |
| Qian, F | 1 |
| Li, P | 1 |
| Xu, X | 1 |
2 other studies available for hypericin and Alzheimer Disease
| Article | Year |
|---|---|
Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Diabetes Mellitus, Type 2; Drug Repositioning; Human | 2023 |
Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anthracenes; Cell Line; Cognition; Cognition Diso | 2016 |